- Home
- SGC vs AVTX Comparison
SGC vs AVTX Comparison
Compare SGC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- AVTX
- Stock Information
- Founded
- SGC 1920
- AVTX 2011
- Country
- SGC United States
- AVTX United States
- Employees
- SGC N/A
- AVTX N/A
- Industry
- SGC Apparel
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- AVTX Health Care
- Exchange
- SGC Nasdaq
- AVTX Nasdaq
- Market Cap
- SGC 215.7M
- AVTX 248.3M
- IPO Year
- SGC N/A
- AVTX 2015
- Fundamental
- Price
- SGC $9.24
- AVTX $15.93
- Analyst Decision
- SGC Strong Buy
- AVTX Strong Buy
- Analyst Count
- SGC 3
- AVTX 9
- Target Price
- SGC $17.33
- AVTX $30.14
- AVG Volume (30 Days)
- SGC 44.6K
- AVTX 378.5K
- Earning Date
- SGC 11-03-2025
- AVTX 11-06-2025
- Dividend Yield
- SGC 6.17%
- AVTX N/A
- EPS Growth
- SGC N/A
- AVTX N/A
- EPS
- SGC 0.36
- AVTX N/A
- Revenue
- SGC $565,017,000.00
- AVTX $192,000.00
- Revenue This Year
- SGC $1.63
- AVTX N/A
- Revenue Next Year
- SGC $3.28
- AVTX N/A
- P/E Ratio
- SGC $25.15
- AVTX N/A
- Revenue Growth
- SGC N/A
- AVTX N/A
- 52 Week Low
- SGC $8.79
- AVTX $3.39
- 52 Week High
- SGC $17.74
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- SGC 37.19
- AVTX 48.59
- Support Level
- SGC $8.79
- AVTX $14.16
- Resistance Level
- SGC $9.44
- AVTX $17.11
- Average True Range (ATR)
- SGC 0.52
- AVTX 1.48
- MACD
- SGC -0.03
- AVTX -0.47
- Stochastic Oscillator
- SGC 19.76
- AVTX 22.92
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).